Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile

  • Connect Biopharma Holdings Limited CNTB has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. 
  • CBP-174, a highly selective, peripherally acting H3 receptor antagonist drug candidate, is in development to treat pruritus (itch) associated with allergic and inflammatory skin diseases, including atopic dermatitis.
  • CBP-174, administered orally, was observed to be safe and well-tolerated across eight dose escalation cohorts evaluated up to a maximum dose of 16 mg or placebo. 
  • Also See: Connect Biopharma Sees CBP-201 Topline Data From China Atopic Dermatitis Trial This Year.
  • There were no serious adverse events, reported adverse events were predominantly mild in severity, and no dose-limiting toxicities were identified. 
  • Other safety parameters, including vital signs, ECGs, and laboratory results, showed no clinically notable safety findings. 
  • Pharmacokinetics of CBP-174 exhibited rapid absorption with dose-proportional increases in exposure followed by linear elimination.
  • Price Action: CNTB shares are up 1.05% at $1.45 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!